SLC6A4 and fatty liver disease: In this scenario, in vivo study demonstrated that transgenic mice overexpressing SLC6A4 are lighter and shorter than controls [28]; on the other hand, Slc6a4 knockout mice develop late-onset obesity, hepatic steatosis, glucose intolerance, and insulin resistance [29].